Jon Napitupulu

Polaryx Therapeutics has unveiled late-breaking preclinical data for PLX-200, an oral formulation of gemfibrozil, in a Krabbe disease mouse...

Polyrizon, a preclinical-stage biotech developing intranasal hydrogel “biological mask” technologies, has signed a non-binding memorandum of understanding to acquire...

ProQR Therapeutics will rotate co-founder Dinko Valerio and director Alison Lawton off its board at the company’s 2026 annual...

Torii Pharmaceutical, a Shionogi subsidiary, has launched Ycanth in Japan for molluscum contagiosum following Japanese approval in September 2025....

BioSyent is acquiring Oral Science, a Canadian dental-focused distributor, for $25.5 million in cash and stock, with additional contingent...

Memo Therapeutics has signed a strategic collaboration and exclusive option-to-license agreement with CSL to advance recombinant polyclonal IgG products...

Inotiv posted first-quarter fiscal 2026 revenue of $120.9 million, up 0.8% year over year, as double‑digit growth in Discovery...

Veru plans to initiate a 200-patient Phase 2b study of enobosarm as an add-on to GLP-1 receptor agonists in...

Denali Therapeutics unveiled new data across its lysosomal storage disorder portfolio and confirmed commercial readiness ahead of an April...

Ocular Therapeutix will unveil 52-week topline data from SOL-1, its Phase 3 superiority trial of the intravitreal axitinib hydrogel...